Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Stock Falls 16% In a Month

January 19, 2022

The clinical stage biopharmaceutical company Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) has seen its stock go through a fairly rough time in recent weeks. Over the course of the past month, the stock has tanked by as much as 16% owing to a steady selloff. Trading Data On Monday, MTNB stock moved up 1.30% to $0.8864 with 649k shares, compared to its average volume of 1.22 million shares. The stock has…

Read More >>

Matinas BioPharma Holdings (MTNB) Nominates Kathryn Penkus Corzo for its Board of Members

September 26, 2021

Matinas BioPharma Holdings (NYSEAMERICAN:MTNB), a clinical-stage biopharmaceutical company, dedicated to enhancing intracellular delivery of critical therapeutics via its cutting edge lipid nanocrystal (LNC) platform delivery technology, has just nominated Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors. The election is scheduled to take place at the 2021 Annual Meeting of Stockholders on November 1, 2021. As of now, Ms. Corzo is a partner at Takeda…

Read More >>